论文部分内容阅读
肿瘤浸润性淋巴细胞(Tumor Infiltrating lymphocytes TIL)在体外经IL—2(白细胞介素2)激活后可大量扩增,并对自身肿瘤细胞具有高度特异性杀伤活性,亦可分泌多种细胞因子协同抗肿瘤作用显著增加,且毒副作用较小,因此近年来有关TIL的实验研究及临床过继免疫治疗应用引起人们的广泛关注。 自1992年我们从晚期肺癌及胰腺癌患者
Tumor infiltrating lymphocytes (TIL) can be massively expanded after being activated by IL-2 (interleukin 2) in vitro, and have a highly specific killing activity against autologous tumor cells, and can also secrete multiple cytokine synergies. The anti-tumor effect is significantly increased, and the toxic and side effects are small. Therefore, in recent years, experimental studies on TIL and clinical applications of adoptive immunotherapy have attracted widespread attention. Since 1992 we have had patients with advanced lung cancer and pancreatic cancer